Retatrutide

What Is Retatrutide?

Retatrutide is an investigational peptide from Eli Lilly that simultaneously agonizes three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. This triple-agonist mechanism represents the next frontier beyond dual-agonists like tirzepatide.

The addition of glucagon receptor agonism is theoretically significant: glucagon increases energy expenditure and fat burning in the liver, complementing the appetite-suppressing and insulin-sensitizing effects of GIP/GLP-1. This combination may address obesity from multiple metabolic angles simultaneously.

As of 2024-2026, retatrutide is in Phase 3 clinical trials. It is NOT FDA-approved and is not available outside of clinical trials through legal channels. Any product claiming to be retatrutide for sale is unregulated.

What The Research Says

Phase 2 trials (published in NEJM, 2023) showed extraordinary results: up to 24.2% average body weight reduction over 48 weeks at the highest dose — surpassing even tirzepatide's SURMOUNT results. This would represent the highest weight loss ever seen from a pharmacological agent if confirmed in Phase 3.

The triple-agonist mechanism also showed significant reductions in liver fat, triglycerides, and blood pressure. Phase 3 trials are underway with results expected in 2025-2026. The cardiovascular outcomes and long-term safety profile are still being established.

📚 Key Reference: PMID: 37342922 (Phase 2 NEJM, 2023)

Common Uses

• Obesity treatment (investigational)
• Metabolic syndrome (investigational)
• MASH/NASH — metabolic liver disease (investigational)

Important Safety Information

As an investigational drug, the full safety profile is not yet established. Phase 2 data showed similar GI side effects to GLP-1 agents (nausea, vomiting, diarrhea). Resting heart rate increases were observed. Long-term safety, including effects on thyroid, cardiovascular system, and bone density, requires Phase 3 evaluation. This drug should only be used within clinical trials.

Questions To Ask Your Provider

1. Is retatrutide available in any clinical trials I might qualify for?
2. How does the triple-agonist mechanism differ from tirzepatide?
3. When is FDA approval expected if Phase 3 trials succeed?
4. What are the known risks from Phase 2 data?
5. How can I find legitimate clinical trial information (ClinicalTrials.gov)?

Regulatory Status

NOT FDA-approved. Investigational New Drug (IND) status in clinical trials. Not legally available outside of registered clinical trials. Any product sold online as 'retatrutide' is unverified research chemical, not pharmaceutical-grade medication. Do not purchase or use.